

Active Astellas EAPs (last updated: March 8<sup>th</sup>, 2018)

Code Number/ Generic name	Brief Protocol Title	Area	ClinicalTrials.gov Identifier
ASP2215/ Gilteritinib	Expanded Access Study of Gilteritinib (ASP2215) in Patients With FMS-like Tyrosine Kinase 3 (FLT3) Mutated Relapsed or Refractory Acute Myeloid Leukemia (AML) or FLT3- Mutated AML in Complete Remission (CR) With Minimal Residual Disease (MRD)	US, Canada	<a href="https://clinicaltrials.gov/ct2/show/study/NCT03070093">NCT03070093</a>